About: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1016/S0140-6736(12)61963-1
Description	Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.Interpretation For women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis. Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.Interpretation For women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis. (en)
Title	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (en)
skos:prefLabel	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (en)
skos:notation	RIV/00064165:_____/13:10196298!RIV14-MZ0-00064165
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	9869
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Petruželka, Luboš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Všeobecná fakultní nemocnice v Praze / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	85385
http://linked.open...ai/riv/idVysledku	RIV/00064165:_____/13:10196298
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	metaanalysis; therapy; Postmenopausal women (en)
http://linked.open.../riv/klicoveSlovo	Postmenopausal women metaanalysis therapy
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[ED9AA0D0C550]
http://linked.open...i/riv/nazevZdroje	Lancet
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	38 (xsd:int)
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	381
http://linked.open...iv/tvurceVysledku	Petruželka, Luboš Pienkowski, Tadeusz Abraham, Mirta Arriagada, Rodrigo Badran, Atef Bonfill, Xavier Bradbury, Joan Clarke, Michael Collins, Rory Davies, Christina Davis, Susan R. Delmestri, Antonella Forbes, John F. Godwin, Jon Gray, Richard Haddad, Peiman Hou, Ming-Feng Inbar, Moshe Khaled, Hussein Kielanowska, Joanna Kwan, Wing-Hong Mathew, Beela S. Medeiros Alencar, Victor Hugo Mittra, Indraneel Müller, Bettina Nicolucci, Antonio Pan, Hongchao Peralta, Octavio Pernas, Fany Peto, Richard Radhika, Ramachandran Raina, Vinod Rajan, Balakrishnan Rubach, Maryna T. Tort, Sera Urrutia, Gerard Valentini, Miriam Wang, Yaochen
http://linked.open...ain/vavai/riv/wos	000316060600030
issn	0140-6736
number of pages	12 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/S0140-6736(12)61963-1

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software